Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FluMist warning letter

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Manufacturing deficiencies at MedImmune's Liverpool, U.K. manufacturing facility for the live intranasal flu vaccine FluMist are not expected to affect the availability of the influenza vaccine for the 2007-2008 flu season, according to FDA. The agency issued a warning letter to MedImmune May 24, citing the company for several significant deviations from current good manufacturing practice in the manufacture of FluMist bulk monovalent lots stemming from an inspection between March 21 and March 27. MedImmune said it expects to have 7 million doses of FluMist available for the 2007-2008 influenza season. The deficiencies will delay approval of MedImmune's sBLA for FluMist seeking to extend the age indication for the vaccine. FDA issued a "complete response" letter for the sBLA May 25, pending resolution of the outstanding issues...

You may also be interested in...



J&J To Power Ahead With 10 Launches In Four Years

 Johnson & Johnson has achieved exceptional growth in recent years, and a raft of new products is set to sustain it further. 

Bayer's Efforts To Pioneer Tumor-Agnostic Market In Europe Held Back

Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.

 

Countries Urged To Open Up On Managed Entry Deals

Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.

UsernamePublicRestriction

Register

PS003585

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel